Cargando…
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
BACKGROUND—: This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus s...
Autores principales: | Dake, Michael D., Ansel, Gary M., Jaff, Michael R., Ohki, Takao, Saxon, Richard R., Smouse, H. Bob, Machan, Lindsay S., Snyder, Scott A., O’Leary, Erin E., Ragheb, Anthony O., Zeller, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823823/ https://www.ncbi.nlm.nih.gov/pubmed/26969758 http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016900 |
Ejemplares similares
-
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results
por: Kichikawa, Kimihiko, et al.
Publicado: (2018) -
Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS
por: Dake, Michael D., et al.
Publicado: (2019) -
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices
por: Dake, Michael D., et al.
Publicado: (2019) -
Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan
por: Ogawa, Yukihisa, et al.
Publicado: (2017) -
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent
por: Dake, Michael D., et al.
Publicado: (2020)